FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194171567> ?p ?o ?g. }

• W3194171567 endingPage "16" @default.
• W3194171567 startingPage "1" @default.
• W3194171567 abstract "Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel.Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups.There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed." @default.
• W3194171567 created "2021-08-30" @default.
• W3194171567 creator A5000053019 @default.
• W3194171567 creator A5001417870 @default.
• W3194171567 creator A5003628873 @default.
• W3194171567 creator A5005758964 @default.
• W3194171567 creator A5005938426 @default.
• W3194171567 creator A5010513682 @default.
• W3194171567 creator A5012324990 @default.
• W3194171567 creator A5014828756 @default.
• W3194171567 creator A5016110170 @default.
• W3194171567 creator A5017307520 @default.
• W3194171567 creator A5017418790 @default.
• W3194171567 creator A5018303392 @default.
• W3194171567 creator A5019668892 @default.
• W3194171567 creator A5023054925 @default.
• W3194171567 creator A5023766989 @default.
• W3194171567 creator A5026634064 @default.
• W3194171567 creator A5028480298 @default.
• W3194171567 creator A5028684820 @default.
• W3194171567 creator A5030514965 @default.
• W3194171567 creator A5032155598 @default.
• W3194171567 creator A5032291905 @default.
• W3194171567 creator A5034669630 @default.
• W3194171567 creator A5035833238 @default.
• W3194171567 creator A5038508170 @default.
• W3194171567 creator A5042163727 @default.
• W3194171567 creator A5044666909 @default.
• W3194171567 creator A5047417686 @default.
• W3194171567 creator A5048495504 @default.
• W3194171567 creator A5049853200 @default.
• W3194171567 creator A5055284771 @default.
• W3194171567 creator A5055474110 @default.
• W3194171567 creator A5056759500 @default.
• W3194171567 creator A5075844360 @default.
• W3194171567 creator A5078809805 @default.
• W3194171567 creator A5080281651 @default.
• W3194171567 creator A5081667950 @default.
• W3194171567 creator A5083072020 @default.
• W3194171567 creator A5083092625 @default.
• W3194171567 creator A5083607138 @default.
• W3194171567 creator A5084916284 @default.
• W3194171567 creator A5086466711 @default.
• W3194171567 creator A5086776746 @default.
• W3194171567 creator A5087211795 @default.
• W3194171567 creator A5091414475 @default.
• W3194171567 date "2021-10-11" @default.
• W3194171567 modified "2023-10-18" @default.
• W3194171567 title "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications" @default.
• W3194171567 cites W1566736068 @default.
• W3194171567 cites W1567779650 @default.
• W3194171567 cites W1880188548 @default.
• W3194171567 cites W1963544199 @default.
• W3194171567 cites W1969462200 @default.
• W3194171567 cites W1976061504 @default.
• W3194171567 cites W1994284635 @default.
• W3194171567 cites W2016846562 @default.
• W3194171567 cites W2020952273 @default.
• W3194171567 cites W2029862269 @default.
• W3194171567 cites W2034447052 @default.
• W3194171567 cites W2034450421 @default.
• W3194171567 cites W2041508558 @default.
• W3194171567 cites W2057503746 @default.
• W3194171567 cites W2068049040 @default.
• W3194171567 cites W2079233624 @default.
• W3194171567 cites W2098418359 @default.
• W3194171567 cites W2103940805 @default.
• W3194171567 cites W2109663791 @default.
• W3194171567 cites W2111321650 @default.
• W3194171567 cites W2112248817 @default.
• W3194171567 cites W2121679642 @default.
• W3194171567 cites W2122229852 @default.
• W3194171567 cites W2126853518 @default.
• W3194171567 cites W2128554753 @default.
• W3194171567 cites W2129337878 @default.
• W3194171567 cites W2130639773 @default.
• W3194171567 cites W2135121745 @default.
• W3194171567 cites W2139040359 @default.
• W3194171567 cites W2147810300 @default.
• W3194171567 cites W2149901050 @default.
• W3194171567 cites W2151444904 @default.
• W3194171567 cites W2152453695 @default.
• W3194171567 cites W2160675720 @default.
• W3194171567 cites W2195122039 @default.
• W3194171567 cites W2266663730 @default.
• W3194171567 cites W2283546675 @default.
• W3194171567 cites W2298073097 @default.
• W3194171567 cites W2388825372 @default.
• W3194171567 cites W2488116111 @default.
• W3194171567 cites W2514556640 @default.
• W3194171567 cites W2618848067 @default.
• W3194171567 cites W2676374412 @default.
• W3194171567 cites W2704483287 @default.
• W3194171567 cites W2737398638 @default.
• W3194171567 cites W2745403546 @default.
• W3194171567 cites W2746434642 @default.
• W3194171567 cites W2747302291 @default.
• W3194171567 cites W2750707608 @default.

• next